NervGen Pharma (NASDAQ:NGEN) Coverage Initiated at Leerink Partners

Investment analysts at Leerink Partners started coverage on shares of NervGen Pharma (NASDAQ:NGEN) in a research note issued to investors on Monday. The brokerage set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners’ price objective would indicate a potential upside of 431.91% from the company’s current price.

NGEN has been the topic of a number of other reports. TD Cowen assumed coverage on shares of NervGen Pharma in a report on Thursday, June 11th. They issued a “buy” rating on the stock. Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. Zacks Research raised shares of NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th. Weiss Ratings assumed coverage on shares of NervGen Pharma in a research note on Friday, April 24th. They issued a “sell (d-)” rating on the stock. Finally, HC Wainwright raised shares of NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.00.

NervGen Pharma Price Performance

Shares of NervGen Pharma stock opened at $1.88 on Monday. The stock’s fifty day simple moving average is $2.48. The company has a market capitalization of $151.59 million and a price-to-earnings ratio of -20.89. NervGen Pharma has a 12 month low of $1.70 and a 12 month high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.